Bloomberg Law
July 19, 2022, 9:36 PM

Exelixis Sues MSN Pharmaceuticals, Asserts Patent Infringement

Jim Silver
Jim Silver
Bloomberg News

Exelixis says lawsuit arises from MSN’s further amendment of its abbreviated new drug application, originally filed with the FDA in 2019 for a generic version of Cabometyx (cabozantinib) tablets.

  • Says MSN’s ANDA now requests approval to market a generic version prior to expiration of Exelixis’ patent
  • NOTE: June 23, Exelixis’ Latest Cabometyx Patent Suit Is Down to Validity


  • Exelixis Inc. shares were little changed in postmarket trading as of 5:32 p.m. New York time
    • The average 12-month price target of $27.08 is 24.0% above the current price
    • 11 buys, 2 sells, 2 holds

To view the source of this ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.